AstraZeneca announced a co-commercialisation agreement with Daiichi Sankyo for MOVANTIK (naloxegol) in the US, in line with the Company’s strategy of delivering value through its own development and commercial capabilities as well as through external collaboration.
MOVANTIK is a first-in-class once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.
|Searching for more deal information? Current Partnering offers the following options:
MOVANTIK was approved by the US Food and Drug Administration in September 2014.
It was descheduled by the US Drug Enforcement Administration in January 2015 and is no longer labelled as a controlled substance.
The launch of MOVANTIK in the US is planned for early April 2015.
Daiichi Sankyo will pay a $200 million up-front fee and subsequent sales-related payments of up to $625 million.
AstraZeneca will be responsible for manufacturing, will book all sales and will make sales-related commission payments to Daiichi Sankyo.
Both companies will be jointly responsible for commercial activities.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies